US · AZN
AstraZeneca PLC
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Cambridge CB2 0AA
- Website
- astrazeneca.com
Price · as of 2025-12-31
$184.74
Market cap 646.31B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $116.87 | -36.74% |
| Intrinsic Value(DCF) | $90.31 | -51.12% |
| Graham-Dodd Method(GD) | $0.80 | -99.57% |
| Graham Formula(GF) | $54.11 | -70.71% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $27.88 | $50.94 | $30.69 | $2.39 | $33.11 |
| 2012 | $30.05 | $43.40 | $8.74 | $0.00 | $0.00 |
| 2013 | $46.14 | $44.73 | $6.14 | $0.00 | $0.68 |
| 2014 | $48.36 | $45.18 | $5.46 | $0.00 | $5.28 |
| 2015 | $44.42 | $41.00 | $5.62 | $0.00 | $1.60 |
| 2016 | $46.48 | $42.51 | $4.91 | $0.00 | $1.98 |
| 2017 | $55.50 | $44.37 | $4.41 | $0.00 | $6.92 |
| 2018 | $70.99 | $50.49 | $3.68 | $0.00 | $5.61 |
| 2019 | $83.26 | $56.76 | $3.41 | $0.00 | $9.28 |
| 2020 | $87.17 | $61.41 | $3.90 | $0.00 | $20.62 |
| 2021 | $111.23 | $68.68 | $93.58 | $0.00 | $1.85 |
| 2022 | $120.98 | $75.00 | $245.13 | $0.00 | $27.53 |
| 2023 | $128.09 | $79.97 | $172.76 | $0.00 | $21.33 |
| 2024 | $152.34 | $95.65 | $126.09 | $0.00 | $57.52 |
| 2025 | $203.73 | $116.87 | $55.36 | $0.80 | $54.11 |
AI valuation
Our deep-learning model estimates AstraZeneca PLC's (AZN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $116.87
- Current price
- $184.74
- AI upside
- -36.74%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$90.31
-51.12% upside
Graham-Dodd
$0.80
-99.57% upside
Graham Formula
$54.11
-70.71% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AZN | AstraZeneca PLC | $184.74 | 646.31B | -37% | -51% | -100% | -71% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| ABBV | AbbVie Inc. | $232.03 | 410.27B | -31% | -54% | — | -83% | 99.26 | -128.28 | 6.86 | 17.08 | — | -4.58 | 83.71% | 34.69% | 6.91% | 15367.27% | 21.58% | 3.14% | -21.12 | 8.08 | 0.67 | 0.41 | 2.26 | -126.00% | 857.00% | -9.00% | 4.25% | 0.44 | 28.25% | 2.78% | 275.80% | 3.01% | 22.78 | 27.13 | 7.90 | 2.52 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| BMY | Bristol-Myers Squibb Comp… | $62.37 | 127.01B | +7% | -50% | — | -56% | 18.03 | 6.89 | 2.64 | 11.25 | — | -5.68 | 67.65% | 26.34% | 14.63% | 40.54% | 17.21% | 7.73% | 2.55 | 8.41 | 1.26 | 1.08 | 2.54 | -17823.00% | -22.00% | -787.00% | 10.10% | 0.60 | 23.02% | 3.97% | 71.50% | 7.05% | 12.89 | 12.74 | 3.40 | 2.41 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| JNJ | Johnson & Johnson | $248.43 | 598.69B | -22% | -48% | — | -38% | 22.52 | 7.40 | 6.41 | 15.83 | 24.88 | -34.24 | 72.78% | 27.17% | 28.46% | 35.03% | 21.82% | 14.13% | 0.59 | 26.36 | 1.03 | 0.69 | 0.71 | 9050.00% | 605.00% | -73.00% | 3.26% | 0.45 | 20.41% | 2.05% | 46.20% | 3.04% | 24.67 | 32.06 | 6.70 | 5.17 |
| LLY | Eli Lilly and Company | $1,052.20 | 992.6B | -41% | +26% | -95% | +11% | 44.29 | 34.45 | 14.03 | 33.98 | 46.14 | 64.76 | 83.79% | 45.56% | 31.66% | 101.36% | 44.87% | 21.59% | 1.60 | 37.34 | 1.58 | 0.78 | 1.27 | 9599.00% | 4470.00% | 206558.00% | 0.98% | 0.48 | 16.90% | 0.59% | 26.10% | 1.04% | 31.97 | 105.82 | 14.57 | 8.36 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
- CEO
- Pascal Claude Roland Soriot
- Employees
- 94.3K
- Beta
- 0.19
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($90.31 ÷ $184.74) − 1 = -51.12% (DCF, example).